|
Diabetes Prevention Program Outcomes Study (DPP/DPPOS)
|
Research Initiative
|
CDC
|
NIDDK, NCI, NHLBI, NIA
|
The Diabetes Prevention Program (DPP) showed that lifestyle change or the drug metformin delay the development of type 2 diabetes. The Diabetes Prevention Program Outcomes Study is studying the long-term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the DPP.
|
|
Diabetic Eye Disease Information Dissemination
|
Public Education Campaign
|
CDC
|
NEI
|
The Centers for Disease Control and Prevention (CDC's) National Diabetes Education Program is part of the National Eye Health Education Program Partnership. The National Eye Institute (NEI) continues to collaborate with CDC and other stakeholders to share information about diabetic eye disease with various communities.
|
|
Diabetic Retinopathy Clinical Research Network
|
Research Initiative
|
OS
|
NEI, NIDDK
|
The Diabetic Retinopathy Clinical Research Network (DRCR.net) is a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema, and associated conditions. The DRCR.net supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well. The network is funded by the National Eye Institute (NEI), and co-funded by the Office of the Secretary (OS), through National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with the Special Funding Program for Type 1 Diabetes Research.
|
|
Diagnosis, Treatment, and Medical Service Utilization in Medicare and Medicaid Population
|
Research Initiative
|
CMS
|
CC
|
Centers for Medicare and Medicaid Services (CMS) and the National Institutes of Health (NIH) Clinical Center (CC) Rehabilitation Medicine (RMD) agreed to collaborate in data-sharing for research, the results of which may be helpful to improve medical-service quality, utilization, and effectiveness for Medicare and Medicaid beneficiaries. CMS will provide electronic data to the NIH Clinical Center, which will perform analyses that are agreed to by both parties.
|
|
Diet-induced Hypomethylation in Preneoplastic Liver/Genetics & Epigenetics of Susceptibility to Non-Alcoholic Fatty Liver Disease
|
Research Initiative
|
FDA
|
NCI
|
The Food and Drug Administration (FDA), the National Center for Toxicological Research, and the National Cancer Institute (NCI) Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that determine susceptibility to the development of hepatocellular carcinoma and to examine epigenetic alterations which may be used as markers of susceptibility to disease development, and whether correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies.
|
|
Digital Quantitation of Plasma Cells in Marrow Biopsies
|
Research Initiative
|
FDA
|
CC
|
This project is a collaboration between the National Institutes of Health (NIH )Clinical Center and the Food and Drug Administration (FDA)that consists of developing software and establishing validations for the automated determination of marrow cellularity and enumeration of plasma cells identified by immunohistochemistry (IHC) using a CD138 antibody. This initial effort should serve as proof of principle for a broader plan to utilize IHC-based automated quantitation of different types of cells in bone marrow core biopsies for diagnosis, prognosis, and therapy monitoring of marrow disorders.
|
|
Disaster Research Response Project (DR2)
|
Research Initiative
|
ATSDR, CDC, FDA, IOS
|
NLM, NIEHS, OD/DPCPSI
|
The NIH Disaster Research Response (DR2) Project is a pilot project aimed at creating an environmental health disaster research system through platforms of ready-to-go research data collection tools and a network of specially trained research responders. This project was developed and will be administered by the NIEHS and NLM. Elements of the system include epidemiologic questionnaires and clinical protocols, specially trained disaster researchers, environmental health disaster research networks, a reach-back roster of subject matter experts, and a support infrastructure that can be activated and deployed during public health emergencies and declared disasters. This effort will not only serve as a model for enhancing environmental health research responses, but will also provide invaluable lessons and platforms for others interested in advancing timely post-disaster research activities.
|
|
Drug Development Interest Group
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, CDC
|
NIAID, FIC, NCI, NHLBI
|
Share information about state of the art and challenges in drug development for infectious diseases
|
|
Drug Induced Liver Injury Network (DILIN)
|
Resource Development
|
FDA
|
NIDDK, NCI
|
Both a prospective and retrospective database containing cases of drug-induced liver disease, the Drug-Induced Liver Injury Network (DILIN) is funded by a cooperative agreement and includes eight clinical centers and a central data coordinating center. One of the goals of the DILIN is to establish a database of well-characterized cases of drug-induced liver injury along with serum, DNA, and tissue samples that will facilitate research on the mechanisms of hepatic injury due to drugs. Cases of liver injury due to herbal medications are also included. The DILIN will develop standardized definitions of drug-induced liver disease and standardization of scoring systems for causality. Three employees of the Food and Drug Administration (FDA) serve as ad hoc members on the committee overseeing the network activities.
|
|
E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI): Developing a Research Agenda
|
Meeting/ Workshop
|
CDC, FDA
|
NHLBI, NCI, NIDA
|
The purpose of this workshop was to develop a research agenda to understand the causes, biology, and long-term health effects of EVALI. National Heart, Lung, and Blood Institute (NHLBI) led the workshop, and National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), National Institutes of Health (NIH) Office of the Director (OD), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA).
|